Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Xencor, Inc.NASDAQ: XNCR

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$12.13M, compared with -$20.18M a year earlier. Trailing-twelve-month EBITDA was -$123.6M.

Context

  • EBITDA amounted to 37.4% of revenue in FY2025, down 131.1 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 8 analysts of -$136.19M (-189.9%) for the fiscal year ending Dec 2026, a slowdown from the +74.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$12.13M+90.0% QoQ
Last fiscal yearDec 2025
-$46.98M+74.8% YoY
LTMJun 2026
-$123.6M-14.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.9%-569.1%-609.0 pp
1 year+74.8%-189.9%-264.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(46.98M) USD
Year-over-year change
+74.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How XNCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -14.3% is the 6th highest of 9, against a peer median of -0.0%.
  • EBITDA amounts to 117.7% of revenue for XNCR, versus a peer median of 147.1%.
XNCR Competitors
EBITDA for XNCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$1.22B USD—-43.3%29.5%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$322.61M USD+243.1%—46.0%
CGENCompugen Ltd.LTM Mar 2026$34.88M USD+463.6%—48.0%
IMCRImmunocore Holdings plcLTM Mar 2026$6.24M USD+2711.1%—1.6%
ADAGAdagene Inc.LTM Jun 2024-$36.06M USD——4420.7%
IPHAInnate Pharma S.A.FY2025-€43.65M EUR+7.0%—1566.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M USD-7.0%—32.2%
IMMPImmutep LimitedFY2025-A$62.88M AUD-41.2%—1246.6%
XNCRXencor, Inc.LTM Jun 2026-$123.6M USD-14.3%—117.7%
NKTRNektar TherapeuticsLTM Jun 2026-$134.39M USD-53.9%—246.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$305.37M USD-38.1%—272652.7%
Peer median (excluding XNCR) —-0.0%-43.3%147.1%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue275.11M164.58M174.62M110.49M125.58M
Cost of Revenue192.51M199.56M0227.69M10.51M
Gross Profit82.6M(34.98M)174.62M(117.19M)115.06M
Gross Margin30.0%-21.3%100.0%-106.1%91.6%
Research & Development192.51M199.56M253.6M227.69M239.43M
Selling, General & Admin38.84M47.49M53.38M58.89M63.64M
Operating Expenses38.84M47.49M306.98M61.22M292.57M
Depreciation & Amortization7.49M8.8M11.5M12.11M10.51M
EBITDA90.14M(45.7M)(101.96M)(186.17M)(46.98M)
EBITDA Margin32.8%-27.8%-58.4%-168.5%-37.4%
Operating Income43.77M(82.47M)(132.36M)(178.41M)(177.5M)
Operating Margin15.9%-50.1%-75.8%-161.5%-141.4%
Interest Income862K4.82M18.63M31.93M27.52M
Interest Expense13K0036.64M31.93M
Other Income / Expenses38.86M27.97M12.73M(56.52M)87.87M
Income Before Tax82.63M(54.51M)(119.63M)(234.92M)(89.42M)
Pre-Tax Margin30.0%-33.1%-68.5%-212.6%-71.2%
Income Tax Expense0673K13.66M1.62M2.5M
Net Income82.63M(55.18M)(133.13M)(232.62M)(91.92M)
Net Margin30.0%-33.5%-76.2%-210.5%-73.2%
EPS (Basic)1.42(0.93)(2.08)(3.58)(1.24)
EPS (Diluted)1.37(0.93)(2.08)(3.58)(1.24)
Weighted Avg Shares58.38M59.65M60.5M65.04M74.24M
Weighted Avg Shares (Diluted)60.5M59.65M60.5M65.04M74.24M

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.